In vivo characterization of a novel Cerasome based multi-modality imaging probe
10.3760/cma.j.issn.2095-2848.2017.11.002
- VernacularTitle:新型多模态硅质体纳米分子探针的在体研究
- Author:
Di FAN
1
;
ping Luo ZHAI
;
Hannan GAO
;
Fan WANG
;
Lin AI
;
Jiyun SHI
Author Information
1. 100050,首都医科大学附属北京天坛医院核医学科
- Keywords:
Molecular probes;
Cerasome;
Indium radioisotopes;
Tomography,emission-computed,single-photon;
Optical imaging;
Mice
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2017;37(11):680-684
- CountryChina
- Language:Chinese
-
Abstract:
Objective To prepare a novel dual-modality imaging probe based on Cerasome nano-materials, and evaluate its in vivo biodistribution and pharmacokinetic properties. Methods ICG encapsu-lated Cerasome was modified with chelating agent DOTA for 111 In-labeling. Normal mice firstly were used for in vivo studies. Animals were sacrificed at different time points after tail vein administration, blood samples were taken and the organs of interest were captured to evaluate the pharmacokinetic properties and in vivo biodistribution of 111 In-ICG-DPDCs. The subcutaneous Lewis lung carcinoma ( LLC ) tumor model in C57BL/6 mouse was established. The tumor-bearing mice were subjected to optical imaging in small animal IVIS and SPECT imaging in small animal nanoScanSPECT/CT system for tumor uptake of 111 In-ICG-DPDCs. Results The size of the nanoparticle probe was about 90 nm, and the 111 In-labeling was successfully per-formed with 99.93% radiochemical purity after purification. 111 In-ICG-DPDCs showed excellent in vitro sta-bility with 97.10% radiochemical purity at 48 h post-purification. In vivo blood clearance experiments showed that 111 In-ICG-DPDCs had a relative long blood circulation time with the fast and slow phase half-lives of 40 and 132.7 min. 111In-ICG-DPDCs accumulated mainly in the liver and spleen, with long retention time. NanoScanSPECT/CT imaging showed that LLC tumors were significantly visualized at 4 h post-injection, and the other major accumulated organs were the liver and spleen, which were consistent with the results of biodistribution. Optical imaging showed significant uptake of the nanoparticle probe in the tumor, confirming the SPECT imaging results. Conclusion The Cerasome based probe designed could be used for tumor SPECT and optical dual-modality imaging, and has potential for therapeutic use.
